English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/214649
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

Title

FADD in cancer: Mechanisms of altered expression and function, and clinical implications

AuthorsMartín-Rubio, José L.; Vela-Martín, Laura; Fernández-Piqueras, José ; Villa-Morales, María
KeywordsFADD
Chromosomal alterations
Mutations
Polymorphisms
Transcription factors
Epigenetic regulation
Posttranslational modifications
Gene expression
Metabolism
Clinical implications
Issue Date29-Sep-2019
PublisherMultidisciplinary Digital Publishing Institute
CitationCancers 11(10): 1462 (2019)
AbstractFADD was initially described as an adaptor molecule for death receptor-mediated apoptosis, but subsequently it has been implicated in nonapoptotic cellular processes such as proliferation and cell cycle control. During the last decade, FADD has been shown to play a pivotal role in most of the signalosome complexes, such as the necroptosome and the inflammasome. Interestingly, various mechanisms involved in regulating FADD functions have been identified, essentially posttranslational modifications and secretion. All these aspects have been thoroughly addressed in previous reviews. However, FADD implication in cancer is complex, due to pleiotropic effects. It has been reported either as anti- or protumorigenic, depending on the cell type. Regulation of FADD expression in cancer is a complex issue since both overexpression and downregulation have been reported, but the mechanisms underlying such alterations have not been fully unveiled. Posttranslational modifications also constitute a relevant mechanism controlling FADD levels and functions in tumor cells. In this review, we aim to provide detailed, updated information on alterations leading to changes in FADD expression and function in cancer. The participation of FADD in various biological processes is recapitulated, with a mention of interesting novel functions recently proposed for FADD, such as regulation of gene expression and control of metabolic pathways. Finally, we gather all the available evidence regarding the clinical implications of FADD alterations in cancer, especially as it has been proposed as a potential biomarker with prognostic value.
Publisher version (URL)http://dx.doi.org/10.3390/cancers11101462
URIhttp://hdl.handle.net/10261/214649
DOIhttp://dx.doi.org/10.3390/cancers11101462
Identifiersdoi: 10.3390/cancers11101462
issn: 2072-6694
Appears in Collections:(CBM) Artículos
Files in This Item:
File Description SizeFormat 
Fernández-PiquerasJ_FADDInCancer.pdf2,92 MBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.